GYN division: How do you explain this?

Discussion in 'Hologic' started by anonymous, Aug 6, 2019 at 5:56 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    From the earnings call transcript: "Global GYN Surgical revenue of $112.2 million increased 4.2%, or 5.2% in constant currency, the division’s highest growth rate in eight quarters."

    What is leading to GYN division's best growth rate in 2 years? Seems like tons of folks on here are complaining. What should I believe?
     

  2. anonymous

    anonymous Guest

    If you take a division down far enough, it’s near impossible to not grow it back somewhat if you were the market leader. Why compare it against 24 months. Let’s see the 36/48/60. Let’s see the numbers from the day Sean and Essex took over the division.
    Steve also used the word Global. Would need to see the break down between US and Global.
     
  3. anonymous

    anonymous Guest

    The numbers are broken out on their press release. Last two quarters have been positive within the US while the first quarter was flat to slightly down.
     
  4. anonymous

    anonymous Guest

    Fair viewpoint, thanks for responding.
     
  5. anonymous

    anonymous Guest

    She's an idiot making up whatever she can to prove her point. Surgical has done well for the past 3+ years.
     
  6. anonymous

    anonymous Guest

    Exactly. That’s why Steve never talks about surgical in earnings calls. What’s to discuss? 3+ years of absolutely killing it. That’s also why all those genius middle managers they brought in from Stryker are leaving now. Job done boys, time to go home!
     
  7. anonymous

    anonymous Guest

    I believe you meant 'has not' done well for the past 2 years. Surgical had double digit growth in 2015 & 2016 and 9% growth in 2017. Then the dumb jocks took over.
     
  8. anonymous

    anonymous Guest

    You’re failing to mention during that growth timeframe a competitor left the market. It’s also hard to grow at that same rate when already capturing such a large portion of the market share. Much of the growth needs to be driven by patient education to drive up procedural volumes. Go after remaining share won’t drive that great of growth and likely results in some erosion of some sort.
     
  9. anonymous

    anonymous Guest

    So you’re suggesting that Hologic surgical growth hit a wall because it was harder... a nice excuse.

    I wonder what would happen if a surgical TM or RM were to try that one on the very same failing leadership group. Wait, no I don’t. They’d be fired.
     
  10. anonymous

    anonymous Guest

    Thermachoice left in January of 2017 and left roughly $20mm up for grabs in the US, much of which we grabbed. Unfortunately it was somewhat offset by Minerva's introduction to the market in late 2016. GEA is definitely a tough market to grow in, but it's your lack of continued strong double digit growth with MyoSure that is really hurting the division.
     
  11. anonymous

    anonymous Guest

    Absolutely shocking that there has not been a real new product in 10+ years. This entire division has been farmed by Mc”Million” for years. Sad thing is it could have been a special story if they would have invested. Novasure and Myosure were blockbusters... there could have been a third, but sadly they continue to farm this business and celebrate line extensions.
     
  12. anonymous

    anonymous Guest

    don’t forget Myosure Reach and Novasure Advance. Those were blockbuster new products hahahahaha. Oh wait never mind those were the same products with a premium price. The blue handle was huge though.
     
  13. anonymous

    anonymous Guest

    It's definitely more difficult to grow, once your market share is higher. The remaining market share is usually held by competitors who customers are fiercely loyal, for whatever reason. The remaining growth potential sometimes isn't even worth trying to pick up - as the resources needed/expended aren't worth it/don't pencil out.